Bao et al. observed that the ATR/CHEK1 pathway was involved in the oncogenic functions of PLK4 in HCC and the authors proposed PLK4/ATR/CHEK1 axis as a potential therapeutic target HCC treatment [30]. This evidence concerns the gene ATR and hepatocellular carcinoma.